Clinical trial · no report yet · Phase 2
NCT06053658
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
- NCT06053658 ↗
- Recruiting
- M.D. Anderson Cancer Center
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Bluesky threads | 13 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Renal Cell Carcinoma
- Interventions
- Tivozanib; Nivolumab
- Arms
- Combination Tivozanib and Nivolumab · Experimental
- Enrollment
- 48 (estimated)
- Primary outcomes
- Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
- Sponsor
- M.D. Anderson Cancer Center with AVEO Pharmaceuticals, Inc.
- Start
- Jan 5, 2024
- Primary completion
- Nov 1, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06053658 · updated Oct 7, 2026